Artivion, Inc. (NYSE:AORT) Insider John E. Davis Sells 6,457 Shares

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 6,457 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $176,340.67. Following the completion of the sale, the insider now owns 160,631 shares in the company, valued at $4,386,832.61. This represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Artivion Stock Down 0.9 %

AORT traded down $0.22 during mid-day trading on Wednesday, reaching $25.34. 295,834 shares of the stock were exchanged, compared to its average volume of 385,115. The stock has a market capitalization of $1.06 billion, a PE ratio of -1,268.25 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a 1 year low of $18.38 and a 1 year high of $32.33. The company has a 50 day moving average price of $29.68 and a two-hundred day moving average price of $27.83.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC raised its holdings in shares of Artivion by 30.8% in the fourth quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock valued at $1,021,000 after acquiring an additional 8,404 shares in the last quarter. Tidal Investments LLC raised its position in shares of Artivion by 14.5% in the fourth quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock valued at $5,141,000 after buying an additional 22,804 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion during the 4th quarter valued at about $64,000. Point72 Asset Management L.P. acquired a new stake in shares of Artivion during the fourth quarter valued at about $5,573,000. Finally, ProShare Advisors LLC increased its stake in Artivion by 44.7% during the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after buying an additional 3,683 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on AORT shares. Stifel Nicolaus decreased their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Needham & Company LLC dropped their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. JMP Securities restated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Finally, Oppenheimer increased their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artivion has a consensus rating of “Buy” and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.